SAGE-217, A Novel GABA(A) Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies

BACKGROUND: SAGE-217, a novel γ-aminobutyric acid A (GABA(A)) receptor positive allosteric modulator, was evaluated in phase I, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) studies to assess the safety and pharmacokinetics (PK) of SAGE-217 following...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffmann, Ethan, Nomikos, George G., Kaul, Inder, Raines, Shane, Wald, Jeff, Bullock, Amy, Sankoh, Abdul J., Doherty, James, Kanes, Stephen J., Colquhoun, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994455/
https://www.ncbi.nlm.nih.gov/pubmed/31338688
http://dx.doi.org/10.1007/s40262-019-00801-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994455/
https://www.ncbi.nlm.nih.gov/pubmed/31338688
http://dx.doi.org/10.1007/s40262-019-00801-0

Ejemplares similares